SPOREs
Breast
Cores
COHORT STUDIES and DATABASES
Breast Cancer Cohort concentrates its efforts in three areas: (1) enrolling new patients for blood draws, banking of specimens, and clinical data collection; collecting clinical data for patients with banked specimens; and, responding to user requests for data. Our database now includes medical information for approximately 15,003 patients, and baseline survey data on an additional 9,094 patients seen for one-time consultations.
High Risk Cohort manages our Risk Evaluation and Cancer History (REACH) project. Only individuals at highest risk, who are evaluated in the Cancer Risk and Prevention Clinic in the Gillette Center of the Dana-Farber Cancer Institute, are eligible to participate. The Core collects questionnaire data from all clinical subjects. This includes family history and exposure data. Those with highest risk in specific categories are asked to provide 2-3 tubes of blood. These specific categories include strong family cancer history, early age at cancer diagnosis, family clustering of rare cancers with breast cancer, histologic lesions (ADH, LCIS) and therapeutic radiation to the chest (e.g., Hodgkin’s Disease survivors).
Databases are maintained by the Core, and include a “high risk” application in the Clinical Research Information System (CRIS). Both cohorts use the CRIS-linked Specimen Tracking and Inventory Program (STIP) application, thus allowing us to better support translational research projects using fully annotated specimens. Pedigree data for the high-risk cohort is kept in a separate Progeny database that links family pedigrees with cancer risk modeling software and rigorously protects patient confidentiality.
CORIS Report Request Forms
Latest Versions of the report forms to be used to obtain CORIS data.
- Procedures for CRIS & STIP Research Data Report
- CORIS Research Report Request Form
- CORIS Clinical Operations Report Request Form
- CORIS Patient Mailing Request Form
Key Personnel
Jane Weeks, MD - DFCI
Judy Garber, MD, MPH - DFCI
Recent Publications
Yen TW, Kuerer HM, Ottesen RA, Niland JC, Edge SG, Theriault RL, Weeks, JC. Impact of randomized clinical trial results on the use of tamoxifen following breast surgery for ductal carcinoma in situ in the National Comprehensive Cancer Network. J Clin Oncol 2007; 25: 3251-8
Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY, Stewart AK, Edge SB. The ASCO/NCCN quality measures. J Clin Oncol (in press).
Hassett MJ, Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC. Selecting high priority quality measures for breast cancer. Medical Care (in press).
Punglia RS, Hughes ME, Edge SB, Theriault RL, Bookman MA, Wilson JL, Ottesen RA, Niland JC, Weeks JC. Factors associated with guideline-concordance use of radiotherapy after mastectomy in the National Comprehensive Cancer Network. Int J Radiat Oncol Biol Phys (in press)
Wong Y, Ottesen R, Niland J, Hughes M, Theriault R, Edge S, Blayney D, Weeks JC. Continued use of trastuzumab beyond disease progression in the National Comprehensive Cancer Network Presentation at the American Society of Clinical Oncology annual meeting, June 2008.
Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007;44:726-31.
